Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial

E Munzone; A Giobbie-Hurder; B A Gusterson; E Mallon; G Viale; B Thürlimann; B Ejlertsen; G MacGrogan; F Bibeau; G Lelkaitis; K N Price; R D Gelber; A S Coates; A Goldhirsch; M Colleoni; International Breast Cancer Study Group and the BIG 1-98 Collaborative Group

doi:10.1093/annonc/mdv391

Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial

E Munzone, A Giobbie-Hurder, B A Gusterson, E Mallon, G Viale, B Thürlimann, B Ejlertsen, G MacGrogan, F Bibeau, G Lelkaitis, K N Price, R D Gelber, A S Coates, A Goldhirsch, M Colleoni, International Breast Cancer Study Group and the BIG 1-98 Collaborative Group

Afdeling for Patologi DIA

10 Citationer (Scopus)

Abstract

BACKGROUND: We investigated the outcomes of postmenopausal women with hormone receptor-positive, early breast cancer with special histotypes (mucinous, tubular, or cribriform) enrolled in the monotherapy cohort of the BIG 1-98 trial.

PATIENTS AND METHODS: The intention-to-treat BIG 1-98 monotherapy cohort (5 years of therapy with tamoxifen or letrozole) included 4922 women, of whom 4091 had central pathology review. Histotype groups were defined as: mucinous (N = 100), tubular/cribriform (N = 83), ductal (N = 3257), and other (N = 651). Of 183 women with either mucinous or tubular/cribriform tumors, 96 were randomly assigned to letrozole and 87 to tamoxifen. Outcomes assessed were disease-free survival (DFS), overall survival (OS), breast cancer-free interval (BCFI), and distant recurrence-free interval (DRFI). Median follow-up in the analytic cohort was 8.1 years.

RESULTS: Women with tubular/cribriform breast cancer had the best outcomes for all end points compared with the other three histotypes, and had less breast cancer recurrence (97.5% 5-year BCFI) than those with mucinous (93.5%), ductal (88.9%), or other (89.9%) histotypes. Patients with mucinous or tubular/cribriform carcinoma had better DRFI (5-year rates 97.8% and 98.8%, respectively) than those with ductal (90.9%) or other (92.1%) carcinomas. Within the subgroup of women with special histotypes, we observed a nonsignificant increase in the hazard of breast cancer recurrence with letrozole [hazard (letrozole versus tamoxifen): 3.31, 95% confidence interval 0.94-11.7; P = 0.06].

CONCLUSIONS: Women with mucinous or tubular/cribriform breast cancer have better outcomes than those with other histotypes, although the observation is based on a limited number of events. In postmenopausal women with these histotypes, the magnitude of the letrozole advantage compared with tamoxifen may not be as large in patients with mucinous or tubular/cribriform disease.

CLINICALTRIALSGOV: NCT00004205.

Originalsprog	Engelsk
Tidsskrift	Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
Vol/bind	26
Udgave nummer	12
Sider (fra-til)	2442-9
Antal sider	8
ISSN	0923-7534
DOI	https://doi.org/10.1093/annonc/mdv391
Status	Udgivet - dec. 2015

Adgang til dokumentet

10.1093/annonc/mdv391

Andre filer og links

Link to publication in Scopus

Citationsformater

Munzone, E., Giobbie-Hurder, A., Gusterson, B. A., Mallon, E., Viale, G., Thürlimann, B., Ejlertsen, B., MacGrogan, G., Bibeau, F., Lelkaitis, G., Price, K. N., Gelber, R. D., Coates, A. S., Goldhirsch, A., Colleoni, M., & International Breast Cancer Study Group and the BIG 1-98 Collaborative Group (2015). Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 26(12), 2442-9. https://doi.org/10.1093/annonc/mdv391

Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial. / Munzone, E; Giobbie-Hurder, A; Gusterson, B A et al.
I: Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, Bind 26, Nr. 12, 12.2015, s. 2442-9.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Munzone, E, Giobbie-Hurder, A, Gusterson, BA, Mallon, E, Viale, G, Thürlimann, B, Ejlertsen, B, MacGrogan, G, Bibeau, F, Lelkaitis, G, Price, KN, Gelber, RD, Coates, AS, Goldhirsch, A, Colleoni, M & International Breast Cancer Study Group and the BIG 1-98 Collaborative Group 2015, 'Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial', Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, bind 26, nr. 12, s. 2442-9. https://doi.org/10.1093/annonc/mdv391

Munzone E, Giobbie-Hurder A, Gusterson BA, Mallon E, Viale G, Thürlimann B et al. Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2015 dec.;26(12):2442-9. doi: 10.1093/annonc/mdv391

@article{4f17482f6b5d45c1b785615228143232,

title = "Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial",

abstract = "BACKGROUND: We investigated the outcomes of postmenopausal women with hormone receptor-positive, early breast cancer with special histotypes (mucinous, tubular, or cribriform) enrolled in the monotherapy cohort of the BIG 1-98 trial.PATIENTS AND METHODS: The intention-to-treat BIG 1-98 monotherapy cohort (5 years of therapy with tamoxifen or letrozole) included 4922 women, of whom 4091 had central pathology review. Histotype groups were defined as: mucinous (N = 100), tubular/cribriform (N = 83), ductal (N = 3257), and other (N = 651). Of 183 women with either mucinous or tubular/cribriform tumors, 96 were randomly assigned to letrozole and 87 to tamoxifen. Outcomes assessed were disease-free survival (DFS), overall survival (OS), breast cancer-free interval (BCFI), and distant recurrence-free interval (DRFI). Median follow-up in the analytic cohort was 8.1 years.RESULTS: Women with tubular/cribriform breast cancer had the best outcomes for all end points compared with the other three histotypes, and had less breast cancer recurrence (97.5\% 5-year BCFI) than those with mucinous (93.5\%), ductal (88.9\%), or other (89.9\%) histotypes. Patients with mucinous or tubular/cribriform carcinoma had better DRFI (5-year rates 97.8\% and 98.8\%, respectively) than those with ductal (90.9\%) or other (92.1\%) carcinomas. Within the subgroup of women with special histotypes, we observed a nonsignificant increase in the hazard of breast cancer recurrence with letrozole [hazard (letrozole versus tamoxifen): 3.31, 95\% confidence interval 0.94-11.7; P = 0.06].CONCLUSIONS: Women with mucinous or tubular/cribriform breast cancer have better outcomes than those with other histotypes, although the observation is based on a limited number of events. In postmenopausal women with these histotypes, the magnitude of the letrozole advantage compared with tamoxifen may not be as large in patients with mucinous or tubular/cribriform disease.CLINICALTRIALSGOV: NCT00004205.",

author = "E Munzone and A Giobbie-Hurder and Gusterson, \{B A\} and E Mallon and G Viale and B Th{\"u}rlimann and B Ejlertsen and G MacGrogan and F Bibeau and G Lelkaitis and Price, \{K N\} and Gelber, \{R D\} and Coates, \{A S\} and A Goldhirsch and M Colleoni and \{International Breast Cancer Study Group and the BIG 1-98 Collaborative Group\}",

note = "{\textcopyright} The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].",

year = "2015",

month = dec,

doi = "10.1093/annonc/mdv391",

language = "English",

volume = "26",

pages = "2442--9",

journal = "Annals of oncology : official journal of the European Society for Medical Oncology / ESMO",

issn = "0923-7534",

publisher = "Elsevier Limited",

number = "12",

}

TY - JOUR

T1 - Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial

AU - Munzone, E

AU - Giobbie-Hurder, A

AU - Gusterson, B A

AU - Mallon, E

AU - Viale, G

AU - Thürlimann, B

AU - Ejlertsen, B

AU - MacGrogan, G

AU - Bibeau, F

AU - Lelkaitis, G

AU - Price, K N

AU - Gelber, R D

AU - Coates, A S

AU - Goldhirsch, A

AU - Colleoni, M

AU - International Breast Cancer Study Group and the BIG 1-98 Collaborative Group

PY - 2015/12

Y1 - 2015/12

N2 - BACKGROUND: We investigated the outcomes of postmenopausal women with hormone receptor-positive, early breast cancer with special histotypes (mucinous, tubular, or cribriform) enrolled in the monotherapy cohort of the BIG 1-98 trial.PATIENTS AND METHODS: The intention-to-treat BIG 1-98 monotherapy cohort (5 years of therapy with tamoxifen or letrozole) included 4922 women, of whom 4091 had central pathology review. Histotype groups were defined as: mucinous (N = 100), tubular/cribriform (N = 83), ductal (N = 3257), and other (N = 651). Of 183 women with either mucinous or tubular/cribriform tumors, 96 were randomly assigned to letrozole and 87 to tamoxifen. Outcomes assessed were disease-free survival (DFS), overall survival (OS), breast cancer-free interval (BCFI), and distant recurrence-free interval (DRFI). Median follow-up in the analytic cohort was 8.1 years.RESULTS: Women with tubular/cribriform breast cancer had the best outcomes for all end points compared with the other three histotypes, and had less breast cancer recurrence (97.5% 5-year BCFI) than those with mucinous (93.5%), ductal (88.9%), or other (89.9%) histotypes. Patients with mucinous or tubular/cribriform carcinoma had better DRFI (5-year rates 97.8% and 98.8%, respectively) than those with ductal (90.9%) or other (92.1%) carcinomas. Within the subgroup of women with special histotypes, we observed a nonsignificant increase in the hazard of breast cancer recurrence with letrozole [hazard (letrozole versus tamoxifen): 3.31, 95% confidence interval 0.94-11.7; P = 0.06].CONCLUSIONS: Women with mucinous or tubular/cribriform breast cancer have better outcomes than those with other histotypes, although the observation is based on a limited number of events. In postmenopausal women with these histotypes, the magnitude of the letrozole advantage compared with tamoxifen may not be as large in patients with mucinous or tubular/cribriform disease.CLINICALTRIALSGOV: NCT00004205.

AB - BACKGROUND: We investigated the outcomes of postmenopausal women with hormone receptor-positive, early breast cancer with special histotypes (mucinous, tubular, or cribriform) enrolled in the monotherapy cohort of the BIG 1-98 trial.PATIENTS AND METHODS: The intention-to-treat BIG 1-98 monotherapy cohort (5 years of therapy with tamoxifen or letrozole) included 4922 women, of whom 4091 had central pathology review. Histotype groups were defined as: mucinous (N = 100), tubular/cribriform (N = 83), ductal (N = 3257), and other (N = 651). Of 183 women with either mucinous or tubular/cribriform tumors, 96 were randomly assigned to letrozole and 87 to tamoxifen. Outcomes assessed were disease-free survival (DFS), overall survival (OS), breast cancer-free interval (BCFI), and distant recurrence-free interval (DRFI). Median follow-up in the analytic cohort was 8.1 years.RESULTS: Women with tubular/cribriform breast cancer had the best outcomes for all end points compared with the other three histotypes, and had less breast cancer recurrence (97.5% 5-year BCFI) than those with mucinous (93.5%), ductal (88.9%), or other (89.9%) histotypes. Patients with mucinous or tubular/cribriform carcinoma had better DRFI (5-year rates 97.8% and 98.8%, respectively) than those with ductal (90.9%) or other (92.1%) carcinomas. Within the subgroup of women with special histotypes, we observed a nonsignificant increase in the hazard of breast cancer recurrence with letrozole [hazard (letrozole versus tamoxifen): 3.31, 95% confidence interval 0.94-11.7; P = 0.06].CONCLUSIONS: Women with mucinous or tubular/cribriform breast cancer have better outcomes than those with other histotypes, although the observation is based on a limited number of events. In postmenopausal women with these histotypes, the magnitude of the letrozole advantage compared with tamoxifen may not be as large in patients with mucinous or tubular/cribriform disease.CLINICALTRIALSGOV: NCT00004205.

UR - https://www.scopus.com/pages/publications/84949935127

U2 - 10.1093/annonc/mdv391

DO - 10.1093/annonc/mdv391

M3 - Journal article

C2 - 26387144

SN - 0923-7534

VL - 26

SP - 2442

EP - 2449

JO - Annals of oncology : official journal of the European Society for Medical Oncology / ESMO

JF - Annals of oncology : official journal of the European Society for Medical Oncology / ESMO

IS - 12

ER -

Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial

Abstract

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater